Medication Adherence Pilot For Asthma and COPD Reveals Nearly 76 Percent Average Daily Engagement Rate, 92 Percent Satisfaction

Share Article

HealthPrize rewards-based medication adherence solution makes participants “feel good” about taking medications

News Image
Having a chronic condition isn’t fun and is sometimes depressing, and this program gave me something to look forward to and made me feel a part of a group and less isolated.

HealthPrize Technologies, LLC, a leading innovator in medication adherence solutions, announced today the results of a six-month asthma and chronic obstructive pulmonary disease (COPD) pilot that tested engagement with its online and mobile platform. HealthPrize leverages rewards, behavioral economics and gaming dynamics to motivate people to stick with their prescription medications.

Conducted in partnership with RealAge – a leading health and wellness site centered around the groundbreaking RealAge Test®, a scientific but simple-to-take test that calculates how old your body thinks you are – the pilot revealed higher than expected engagement rates, with an average of 7.7 logins per patient per week, and an average 75.7 percentage daily medication self-reporting rate. (If only “active” participants are counted, the self-reporting rate was 89.6 percent.) Further, 92 percent of participants reported that that they would continue with the program for greater than six months if they were able.

According to a 2008 study of 1,812 patients with asthma or COPD, only 13 percent of patients refilled their medication often enough to allow for continuous coverage.1 Given that daily maintenance inhaler use is critical to preventing exacerbations, emergency room visits, and hospitalizations, HealthPrize and RealAge believe that innovative solutions are required to improve outcomes in this population.

A total of 282 adult patients, with a mean age of 53.5, participated in the HealthPrize program, which involved earning points for a number of activities: self-reporting medication taking, completing weekly educational quizzes and surveys, and opening daily educational “Fortune Cookies.” Points were then redeemed in the Rewards Mall for e-certificates and merchandise. Participants also engaged in a monthly Leaderboard competition and weekly PowerPill sweepstakes.

According to one participant, incorporating HealthPrize into her daily medication regimen “really helped me stay on track and made me feel good about taking my meds. Having a chronic condition isn’t fun and is sometimes depressing, and this program gave me something to look forward to and made me feel a part of a group and less isolated.”

Additional results and participant feedback includes:

  •     69 percent demonstrated a daily self-reporting rate between 81 to 100 percent
  •     62 percent ranked their likelihood of recommending the program to others as a 10 (“very likely”) based on a scale of 1-10; 13 percent responded with a 9, and 15 percent with an 8.
  •     63 percent of all participants felt they had learned “a lot” from the medication education component offered in the HealthPrize program
  •     Praise for HealthPrize’s financial and gift reward component was high: “It’s been extremely nice to get an actual award. Especially for low-income patients such as me, this is a great method to achieve compliance.”
  •     Feedback regarding HealthPrize education was also very positive: “…The quiz portion was my favorite. I have always believed that knowledge is power, and in this case, knowledge is also life.”

Commenting on this feedback, Katrina Firlik, MD, HealthPrize’s co-founder and chief medical officer, stated: “It was rewarding to see how our system really became a part of so many people’s lives and had such an impact. This bodes well for our ability to improve medication adherence and to add that critical ‘fun factor’ that other programs lack.”

HealthPrize has several other pilot programs rolling out in 2012 that target a diverse array of conditions, from acne to oncology. These programs will aim not only to engage patients, but also to specifically reward patients for timely refills, and to verify compliance via HealthPrize’s patent-pending automated refill verification system.

Click here for more information about the asthma/COPD pilot study, and visit http://www.healthprize.com to learn more about working with HealthPrize.

Reference: 1Haupt D, Krigsman K, Nilsson JLG. Medication persistence among patients with asthma/COPD drugs. Pharm World Sci (2008) 30:509-514.

About RealAge
RealAge.com is a leading health and wellness site centered around the groundbreaking RealAge Test®, a scientific but simple-to-take test that calculates how old your body thinks you are. The patented test, which launched in 1999 and has been taken by more than 27 million people, is backed by powerful new technology that allows it to be constantly updated with the latest medical studies. Anyone who takes the Test receives a personalized Grow Younger Plan designed to turn back your body clock. The site also offers health tips; dozens of other tests; and practical, inspiring information. RealAge aggressively guards users' privacy and does not share its members' identities with third-party advertisers. RealAge, Inc. is a wholly owned subsidiary of Hearst Entertainment & Syndication, a division of the Hearst Corporation.

About HealthPrize Technologies
HealthPrize Technologies, founded in September 2009, provides an innovative approach to addressing the problem of medication non-adherence with an online and mobile-based program that is fun, engaging and educational. For more information, visit http://www.healthprize.com or call 203-604-6820.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Emma Ludwin
HealthPrize
203-504-8230 107
Email >
Visit website